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The loss of interstitial capillaries is a feature of several
experimental models of renal disease and this contributes to
secondary kidney injury. Angiopoietin-1 is a secreted growth
factor which binds to Tie-2 present on endothelia to enhance
cell survival thereby stabilizing capillary architecture in-vitro.
Previous studies showed that angiopoietin-1 prevented renal
capillary and interstitial lesions following experimental
ureteric obstruction. We tested here the effect of
angiopoietin-1 treatment on capillary loss and associated
tubulointerstitial damage known to follow recovery from folic
acid-induced tubular necrosis and acute renal injury. We
found that delivery of angiopoietin-1 by adenoviral vectors
stabilized peritubular capillaries in folic acid nephropathy but
this was accompanied by profibrotic and inflammatory
effects. These results suggest that the use of endothelial
growth factor therapy for kidney disease may have varying
outcomes that depend on the disease model tested.
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Angiopoietins (Angs) constitute a family of secreted growth
factors that predominantly target endothelia.1 Ang-1 binds to
and phosphorylates the Tie-2 receptor, with context-depen-
dent effects including enhancement of endothelial cell
survival, and capillary stabilization and sprouting. Mice
engineered to overexpress Ang-1 in the skin have more
complex and larger vessels in that tissue,2 whereas Ang-1 null
mutant mice have defective endocardial differentiation and
failure of embryonic vascular remodeling.3 Ang-2 has been
considered an Ang-1 inhibitor, and transgenic Ang-2 over-
expression produces defects resembling Ang-1 null mutants.4
Ang-2 is thought to cause vessel destabilization, which
can be followed either by regression when the milieu is
deficient in vascular endothelial growth factor (VEGF), or
angiogenesis when the environment is VEGF repleted.1
Functions of the Tie-1 receptor are less clear than those of
Tie-2; however, both Ang-1 and an engineered variant called
cartilage oligomeric matrix protein-Ang-1, lead to Tie-1
phosphorylation in the presence of Tie-2 and Tie-1 can
downregulate Tie-2-driven intracellular signaling and en-
dothelial survival.5,6
Angiopoietin-1, Ang-2, Tie-1, and Tie-2 are expressed
from the embryonic inception of the mammalian kidney,
with transcript levels peaking perinatally and present, at
lower levels, in adulthood.7–9 Ang-1 is expressed in
metanephric mesenchymal cells,9,10 diverse developing tu-
bules,8 and mature podocytes.11,12 Tie-2 and Tie-1 are
expressed by glomerular and peritubular capillaries, and the
fact that Tie-2 tyrosine phosphorylation is detected in
kidneys of healthy adults8 is consistent with the idea that
Ang signaling may maintain the integrity of the renal
vasculature even after development is complete.
A depletion of interstitial capillaries occurs in chronically
failing human kidneys,13,14 and a similar association has been
documented in several animal models of chronic renal
damage including those induced by ureteric obstruction15
and folic acid (FA)-induced nephrotoxicity.16 In rodents,
systemic administration of high-dose FA leads to it under-
going glomerular filtration and there follows widespread
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tubular damage: in the next 2 days, a burst of epithelial
proliferation leads to regeneration of some tubules. However,
over the next few weeks, there is incomplete healing
evidenced by patchy interstitial fibrosis, tubule atrophy, loss
of peritubular capillaries, and tissue hypoxia.16–18
We previously analyzed Ang expression in FA nephropathy
in adult mice.18 Ang-1 protein was detectable in whole
kidneys of controls and increased at 1–14 days after FA
administration. In controls, Ang-1 immunoreactivity was
detected between cortical tubules and upregulated in cortical
arteries, cortical distal tubules, and glomerular parietal
epithelia 1–3 days following FA administration. At later
times, Ang-1 was detected in areas of cortical tubulointer-
stitial lesions. In contrast, although Ang-2 could be detected
in whole control kidneys, the levels appeared unaffected
during the course of FA nephropathy.18 The alterations in
Ang-1 were initially associated with an increase in peritubular
capillary proliferation at 2–3 days after FA administration.18
However, capillary number was not maintained and attrition
of peritubular endothelia occurred 2 weeks later.16 On the
basis of these results, we conclude that FA nephropathy is an
‘Ang-1-rich’ disorder but that, despite this, capillary fallout
eventually occurs. We reasoned that upregulated endogenous
Ang-1 was an incompletely effective compensatory response
and predicted that administration of exogenous Ang-1 (using
an adenoviral system)19 would prevent capillary loss.
RESULTS
Induction of folic acid nephrotoxicity
Two days after the administration of FA (that is, day 7 of
the protocol outlined in Figure 1) in both the adenovirus
transducing the reporter gene, green fluorescence protein
(Ad-GFP) and Ang-1* (Ad-Ang-1*) groups, mice were in
severe renal failure, assessed by plasma creatinine and urea
levels (Table 1). There was a tendency for creatinine and urea
levels to be higher in the Ad-Ang-1* compared with the
Ad-GFP-administered animals (Table 1). Visual inspection
at autopsy of FA-exposed animals revealed swollen kidneys
with pale surfaces and kidney/body weight ratios in FA-
administered animals were approximately 40% greater than
sham controls (Table 1). Histological examination (Figure 2a
and b) showed marked kidney damage in all animals
administered FA, with flattened proximal and distal tubule
epithelia and casts in tubule lumens. Transmission electron
microscopy revealed that kidneys exposed to FA contained
prominent cortical interstitial areas: profiles of peritubular
capillaries rarely contained red blood cells and the zone
between these capillaries and tubules appears expanded and
contained cells with profiles characteristic of macrophages
(Figure 2c and d). The area of the kidney cortex containing
macrophages was increased compared with sham controls
following FA administration, but neutrophils were not
altered (Table 2, Figure 3a and b). The amount of positive
aniline blue areas following Masson’s trichrome staining was
significantly increased in the kidneys of FA-exposed animals
compared with sham controls, as were both collagen I
expression and collagen III expression as assessed by
immunohistochemistry (Table 2, Figure 3c–e). In sham
control kidneys, periglomerular a-smooth muscle actin (a-
SMA) immunostaining was rarely observed, and there were
nonsignificant increases in this parameter in kidneys of FA-
administered animals (Table 2, Figure 3f). Capillary area was
significantly increased in the kidneys of animals exposed to
FA compared with sham controls (Table 2, Figure 3g). Levels
of VEGF-A protein were significantly decreased in FA-
administered kidneys, compared with sham controls but
elevated in the serum (Table 2, Figure 3h and i). There was no
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Figure 1 | Experimental Groups I–III.
Table 1 | Kidney weights and renal excretory function
Group I Group II Group III
PBScNaHCO3 Ad-GFPcFA Ad-Ang-1*cFA
Day 26 (n=7) Day 7 (n=8) Day 26 (n=7) Day 7 (n=8) Day 26 (n=7)
Kidney/body weight ( 100) 0.61±0.01 1.08±0.06a 0.60±0.02b 1.08±0.04a 0.54±0.03c,d
Serum creatinine (mM) 22±1 123±27a 23±1b 162±38a 25±1a,d
Blood urea (mM) 7.2±0.1 64.8±11.8a 8.0±0.6b 68.9±10.6a 11.4±0.6a,d,e
Ad-Ang-1*, adenovirus angiopoietin-1*; Ad-GFP, adenovirus green fluorescence protein; FA, folic acid; PBS, phosphate-buffered saline.
Adenovirus (Ad-GFP or Ad-Ang-1*) or vehicle only (PBS) was administered at day 0. FA or vehicle only (NaHCO3) was administered at day 5. Animals from Group II (negative
control adenovirus group) and Group III (active adenovirus group) were killed at days 7 and 26 (i.e., respectively, 2 days and 3 weeks after induction of nephrotoxicity, which
was on day 5), whereas all animals in Group I (sham controls) were killed at day 26. All data are given as mean±s.e.m.
aPo0.01 compared with Group I.
bPo0.01 compared with Group II data at day 7.
cPo0.05 compared with Group I.
dPo0.01 compared with Group III data at day 7.
ePo0.01 compared with Group II data at day 26.
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significant difference between Ad-Ang-1* and Ad-GFP
administered animals in any histological parameter (Table 2,
Figure 3a–g) or in VEGF-A levels (Table 2, Figure 3h and i) 2
days following FA administration.
Recovery from acute FA-induced nephrotoxicity
On day 26 of the protocol (that is, 3 weeks after FA exposure)
serum levels of 60±15 ng/ml Ang-1* were recorded in
animals treated with Ad-Ang-1*. As expected, because
Ang-1* does not occur naturally, no Ang-1* was detectable
in serum of sham controls or animals administered Ad-GFP.
Ang-1* therapy had no effect on mortality after FA
administration compared with the control virus, with one
animal in both Groups II and III dying in the first few days
following FA injection. By day 26, we documented a striking
recovery in renal excretory function in animals exposed to FA
with blood creatinine and urea levels in the Ad-GFP group
not significantly different to sham controls; but there
remained a significant, even though modest, increase in
blood urea levels in the Ang-1*-treated animals (Table 1).
Overnight excretion of albumin measured at day 18 or 19 in
both Ad-GFP and Ad-Ang-1* groups (22±6 and 27±3mg
per 18 h, respectively) was not significantly different to that of
sham controls (35±9mg per 18 h). The swelling evident in
FA-exposed kidneys at day 7 significantly subsided, as
confirmed by measurement of kidney/body weight ratios
(Table 1). It was notable, however, that focal, depressed areas
on the kidney surface were found in the FA-exposed groups
but not in the kidneys of sham controls. These lesions were
more prominent in the Ad-Ang-1* compared with the Ad-
GFP groups, and this ‘tissue contraction’ was reflected in the
fact that kidney/body weight ratios were significantly lower
than sham controls in the Ad-Ang-1* group (Table 1).
Effects of adenoviral Ang-1* therapy on peritubular
capillary attrition
Histologically, on day 26 in both the Ad-GFP and the Ad-
Ang-1* groups that had undergone FA exposure, most
cortical tubules now appeared intact and had therefore
regenerated (Figure 4a–c). Kidney cortices of animals
administered FA preceded by Ad-GFP contained an
Sham control Folic acid
PAS
Tansmission Em
a b
c d ∗
∗
∗
Figure 2 | Renal histology 2 days after FA exposure. (a, b) PAS
staining on a representative sham control and FA kidney after
2 days. Marked kidney damage was noted in all animals
administered FA, with flattened proximal and distal tubule
epithelia with casts in tubule lumens. Bar¼ 50mm.
(c, d) Transmission electron microscopy. Kidneys of animals
exposed to FA contained prominent cortical interstitial areas (*)
with monocyte-like cells (arrowed).
Table 2 | Histological parameters
Group I Group II Group III
PBScNaHCO3 Ad-GFPcFA Ad-Ang-1*cFA
Day 26 (n=7) Day 7 (n=8) Day 26 (n=7) Day 7 (n=8) Day 26 (n=7)
Periglomerular a-SMA expression (%) 0.6±0.5 1.4±0.6 6.0±2.2a,b 2.0±0.8 39.8±6.5c,d,e
Area with aniline blue positive staining (%) 5.9±0.1 26.3±4.5c 14.1±0.6c 26.6±2.6c 25.1±3.8c,f
Collagen I area (%) 0.6±0.1 5.5±0.3c 1.5±0.4b 5.0±0.7c 4.6±0.5c,f
Collagen III area (%) 2.7±0.3 7.3±0.3c 3.6±0.7b 6.4±0.5c 7.0±0.4c,f
Capillary area (%) 10.8±0.3 13.3±0.3c,f 8.4±0.4c 13.6±0.2c 12.2±0.3c,d,f
Renal VEGF levels (pg/mg of protein) 894±29 388±58.1c 1021±122b 385±45c 993±117g
Serum VEGF levels (pg/ml) 32±5 130±24c 56±10a,h 123±16c 61±10a,g
Area containing macrophages (%) 4.6±1.2 13.2±1.1c 22.1±3.8c 15.1±1.7c 38.6±6.0c,e,g
Area containing neutrophils (%) 1.4±0.6 1.4±0.3 6.1±0.5b,c 1.3±0.4 12.6±2.4b,c,f,g
Ad-Ang-1*, adenovirus angiopoietin-1*; Ad-GFP, adenovirus green fluorescence protein; FA, folic acid; PBS, phosphate-buffered saline; a-SMA, a-smooth muscle actin; VEGF,
vascular endothelial growth factor.
Adenovirus (Ad-GFP or Ad-Ang-1*) or vehicle-only (PBS) was administered at day 0. FA or vehicle only (NaHCO3) was administered at day 5. Animals from Group II (negative
control adenovirus group) and Group III (active adenovirus group) were killed at days 7 and 26 (i.e., respectively, 2 days and 3 weeks after induction of nephrotoxicity which
was on day 5), whereas all animals in Group I (sham controls) were killed at day 26. All data are given as mean±s.e.m.
aPo0.05 compared with Group I.
bPo0.01 compared with Group II data at day 7.
cPo0.01 compared with Group I.
dPo0.05 compared with Group III data at day 7.
ePo0.05 compared with Group II data at day 26.
fPo0.01 compared with Group II data at day 26.
gPo0.01 compared with Group III data at day 7.
hPo0.05 compared with Group II data at day 7.
These data are shown graphically in Figure 3.
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attenuated network of peritubular capillaries when compared
with sham controls: however, this attrition of the peritubular
network was prevented in animals administered Ad-Ang-1*
(Table 2, Figures 3g and 4d–f). Renal levels of VEGF-A were
restored to sham control values in both Ad-GFP and Ad-Ang-
1* groups (Table 2, Figure 3h). Circulating VEGF-A levels in
FA-administered animals had fallen toward, but was still
significantly above, sham control levels (Table 2, Figure 3i).
Similar Ang-1 mRNA levels were found in animals
administered either Ad-GFP or Ad-Ang-1* prior to FA
administration (Figure 5a).
Effects of adenoviral Ang-1* therapy on renal fibrosis
In FA-exposed kidneys on day 26 of the protocol, there was
patchy interstitial areas staining blue with Masson’s tri-
chrome (Figure 4a–c), and quantification revealed a marked
increase compared with sham controls: this staining was
enhanced in the Ad-Ang-1* compared with the Ad-GFP
groups (Table 2, Figure 3c). Ad-GFP animals tended to have
higher renal cortical collagen I and III deposition compared
with sham controls and Ad-Ang1* animals showed more
significant increases (Table 2, Figures 3d and e, and 4g–i).
Periglomerular a-SMA expression was also altered, with an
average of 6% of affected glomeruli in the Ad-GFP group and
40% in the Ad-Ang-1* group (Table 2; Figures 3f, 6a and b),
and a significant increase in total a-SMA protein in the FA
nephropathy kidneys of the Ad-Ang-1* compared with the
Ad-GFP groups (Figure 6c and d). By comparing mRNA
levels in kidneys from Groups II and III, we detected
significantly increased levels of a battery of fibrotic genes
(Figure 5b–e), in animals administered Ad-Ang-1*.
Effects of adenoviral Ang-1* therapy on renal inflammation
On day 26 of the protocol, the area of the kidney containing
macrophages and neutrophils was increased in animals
exposed to FA compared with sham controls (Table 2,
Figures 3a and b, and 4j–o). This increase was significantly
accentuated in the Ad-Ang-1* compared with the Ad-GFP
groups. MCP-1 (monocyte chemoattractant protein-1)
serum levels were increased in the Ad-Ang-1* compared
with the Ad-GFP groups (644±128 and 323±117 ng/mg
total kidney protein, respectively, Po0.05). Using reverse-
transcripitase polymerase chain reaction (RT-PCR), Ang-2,
Tie-1, and Tie-2 transcripts were detected in cultured murine
macrophages (Figure 7a). The expression of Tie-1 and Tie-2
was confirmed by western blotting (Figure 7b).
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Figure 3 | Quantification of histological parameters and VEGF-A levels. Graphical representation of (a) area containing macrophages;
(b) area containing neutrophils; (c) area with aniline blue staining; (d) collagen I area; (e) collagen III area; (f) periglomerular a-SMA
expression; (g) capillary area; (h) renal VEGF levels; (i) serum VEGF levels. Data are displayed from Group I (sham controls) at day 26 (white
bars), Group II (negative control adenovirus group) at day 7 (gray and white striped bars) and day 26 (gray bars), and Group III (active
adenovirus group) at day 7 (black and white striped bars) and day 26 (black bars). All data are given as mean±s.e.m. aPo0.01 compared
with Group I; bPo0.05 compared with Group I; cPo0.01 compared with Group II data at day 7; dPo0.05 compared with Group II data at
day 7; ePo0.01 compared with Group III data at day 7; fPo0.05 compared with Group III data at day 7; gPo0.01 compared with Group II
data at day 26; hPo0.05 compared with Group II data at day 26.
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Effects of the control (GFP) adenovirus on renal function,
fibrosis, and inflammation
In parallel experiments, we determined whether administra-
tion of the negative control adenovirus (Ad-GFP; Group II)
might alter the course of FA nephropathy by comparison
with a fourth experimental group, namely mice administered
adenovirus vehicle only prior to exposure to FA (n¼ 8). Our
data indicated that chronic FA nephropathy, as assessed by
kidney weight, blood urea and creatinine, markers of fibrosis,
and interstitial inflammation measured at day 26 were not
PBS/NaHCO3 (I)–26 days GFP/FA (II)–26 days Ad-Ang-1* FA (III)–26 days
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Figure 4 | Histological observations at day 26 of protocol. (a–c) Masson’s trichrome staining. (a) Minimal aniline blue staining areas
qin Group I sham controls. Note progressively more extensive blue areas in FA kidneys from animals administered Ad-GFP (b) and
Ad-Ang-1* (c). (d–f) PECAM-1 immunohistochemistry. (d) PECAM-1 immunoreactive capillary network (black) around cortical tubules in a
sham control kidney. (e) Kidneys of animals injected with Ad-GFP prior to FA had patchy PECAM-1 immunostaining. (f) Administration
of Ad-Ang-1* prior to FA was associated with a more regular peritubular PECAM-1 network. (g–i) Collagen III immunohistochemistry.
(g) Sham control kidneys contained occasional positive staining around glomeruli. (h) Kidney from mouse administered Ad-GFP prior to
FA showed modest increases in collagen III signal in the kidney cortex. (i) Marked increase in collagen III observed in mice administered
Ad-Ang1* prior to FA. To assess inflammation, macrophages (j–l) or neutrophils (m–o) were immunodetected (brown signal). (j, m) Sham
control kidney. (k, n) Kidney from mouse administered Ad-GFP prior to FA shows modest increases in signals. (l, o) Kidney from mouse
administered Ad-Ang-1* prior to FA shows marked increases in signals. Bars¼ 100mm.
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modified by Ad-GFP administration (data not shown and
available on request).
DISCUSSION
Our data demonstrate that prior administration of Ad-Ang-
1* does appear to protect the kidney cortical microvascu-
lature in the chronic phase of FA nephropathy as evidenced
by the maintenance of a regular network of platelet
endothelial cell adhesion molecule-1 (PECAM-1) immunos-
taining. Interestingly, we have also observed that Ad-Ang-1*
administration to healthy (that is, non-nephropathic) mice is
associated with a modest increase in cortical peritubular
capillary area (DA Long, AS Woolf, personal observations).
This effect might be due to an elevation in endothelial
number due to Ang-1 directly enhancing proliferation20 or
preventing endothelial apoptosis.21 In addition, in vitro,
recombinant Ang-1 stabilizes capillaries and enhances
PECAM-1 localization in junctions between endothelia,22 if
this effect also occurs in vivo, it could explain some of the
‘preservation’ of peritubular capillaries by Ad-Ang-1* therapy
in the FA model.
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Figure 6 | a-SMA expression on day 26 of protocol. (a) In
kidneys of sham control animals (Group I), a-SMA expression
(brown) was confined to arterioles (a) and glomeruli (g) were
negative. (b) In FA-administered animals (Groups II and III), a
significant subset of glomeruli showed periglomerular sclerosis, as
assessed by a-SMA immunostaining (arrows). Bar¼ 50mm. (c, d)
Western blotting and densitometry for a-SMA. Note significant
(**indicates Po0.01) upregulation of the 42-kDa protein in
animals administered Ad-Ang-1* (Group III) compared with
Ad-GFP (Group II) prior to FA exposure.
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Figure 7 | Ang and Tie expression in cultured macrophages.
(a) RT-PCR. Ang-2, Tie-1, and Tie-2 (but not Ang-1) transcripts
were detected in mouse macrophage cells (M). Adult mouse
kidney tissue (K) was used as a positive control for all four
genes.8 Negative controls consisted of no cDNA (C) or no
reverse transcriptase (RT). (b) Western blotting for Tie-1 and
Tie-2 on mouse macrophages. A band of the expected size
(approximately 130 kDa) was observed for both Tie-1 and Tie-2.
b-Actin was used as a housekeeping gene.
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We also found that the same treatment enhanced renal
fibrotic responses. FA chronic nephropathy in the C57Bl/6J
mouse strain was associated with significant incidence of
periglomerular a-SMA expression. Similar observations have
been reported in human kidneys affected by IgA nephro-
pathy23 and in a radiation model of nephropathy,24 where it
is associated with glomerulotubular neck narrowing, a lesion
that is postulated to reduce glomerular filtration. The
incidence of periglomerular a-SMA expression 3 weeks after
FA exposure was strikingly increased after Ad-Ang-1*
administration, and associated with an increase in blood
urea levels, presumably reflecting worse renal excretory
function. We also observed that, in the context of FA
nephropathy, Ad-Ang-1* administration increased levels of
total kidney a-SMA protein and interstitial fibrosis.
Perhaps an enhanced ratio of Ang-1/Ang-2 preserves renal
endothelia but at the expense of an unwanted increase of
associated supporting cells. It is interesting to draw a parallel
between the enhanced fibrosis induced by exogenous Ang-1*
in the current model of adult nephropathy, with the increased
numbers of pericyte-like cells in the interstitium of neonatal
kidneys of mice with genetic ablation of Ang-2.25 Potential
sources of these extra fibromuscular-like cells could be
activated resident fibroblasts,26 perivascular adventitial
cells,27 endothelial cells themselves,28 migrating bone marrow
stem cells,29 or even tubule cells, which undergo mesench-
yme–epithelial transition.30 We speculate that, in the current
scenario, the source of additional fibromuscular cells after
Ang-1 administration is unlikely to be the bone marrow,
because Ang-1 is reported to stabilize niches in that tissue.31
In addition, resident epithelia are unlikely to be directly
induced to transdifferentiate by Ang-1, because they do not
appear to express Tie-2, both in the healthy kidney and in FA
nephropathy.18 Instead, we favor the idea that these cells may
derive from endogenous mesenchymal/interstitial cells, and
Ang-1 may have indirect1,3 or even direct actions32,33 to
stimulate such cells to migrate and acquire fibromuscular/
pericyte-like characteristics.
Ad-Ang-1* administration in the context of FA nephro-
pathy was associated with increases in interstitial neutrophils
and macrophages, as well as elevated levels of MCP-1. These
observations, therefore, at first appeared somewhat surprising
as several studies have suggested that the actions of Ang-1 are
anti-inflammatory. In vitro, recombinant Ang-1 decreases
permeability between endothelia by making endothelial
cell–cell junctions more stable.22 In vivo, Ad-Ang-1* decreases
the number and size of gaps between endothelia in tracheal
venules induced to leak by bradykinin34 and inhibited leakage
induced by other inflammatory stimuli.19 Ang-1 can reduce
leukocyte adhesion to endothelia correlating with reduced
expression of intercellular adhesion molecule-1, vascular cell
adhesion molecule-1, and E-selectin.35 Other studies, how-
ever, provide data showing that Ang-1 can have pro-
inflammatory effects. For example, aortic rings treated with
Ang-1 upregulated MCP-1, TNF-a (tumor-necrosis factor-
a), and IL-1b (interleukin-1b).36 We also demonstrated that,
in vitro, murine macrophages express Tie-1 and Tie-2,
consistent with the idea that they might be direct targets
for Ang-1 in vivo. The results accord with the observation
that a specific monocyte lineage expresses Tie-2.33 Further-
more, the expression of Tie-2 is upregulated on macrophages
in rheumatoid arthritis.37 Neutrophils also have been shown
to express Tie-2 and Angs can promote recruitment of these
cells.38 Finally, in accord with a recent report,39 we found that
cultured murine macrophages themselves express Ang-2, and
this has itself been implicated in enhancing inflammation
and necrosis.40–42
Vascular endothelial growth factor-A itself has important
effects on endothelia, enhancing survival and proliferation.1
Furthermore, the blood endothelial actions of the Angs are
dependent on ambient VEGF-A levels.1 In addition, the
monocyte–macrophage lineage expresses VEGFR1 (Flt1), and
VEGF-A enhances macrophage migration;43 similar observa-
tions have been made for neutrophils.44 Previously,16 we
reported that both renal cortical VEGF-A mRNA and
protein, as assessed by northern and western blotting, fell
significantly in the first few days following FA administration
to adult CD1 mice. The mRNA downregulation was
confirmed by in situ hydridization for VEGF-A and, as
assessed by immunohistochemistry, VEGF-A was detected in
podocytes and subsets of cortical tubules in controls. Also,
the intensity of signal in these sites fell after FA administra-
tion. In the current study using adult C57Bl/6J mice, we
measured VEGF-A using ELISA (enzyme-linked immuno-
sorbent assay). VEGF-A was depleted within kidney tissue in
the first days after FA administration, and therefore capillary
endothelia may receive reduced VEGF-A signals, with a
tendency to regression. We additionally found that circulat-
ing VEGF-A was increased and we speculate that this may be
caused by damaging effects of FA on systemic vasculature,45
with VEGF-A originating in vessels outside the kidney.46
Increased circulating VEGF-A in the FA model may enhance
migration of macrophages and neutrophils, and, indeed, we
found that these cells were increased in kidneys damaged by
FA. Furthermore, these increases were accentuated by
administration of Ang-1*. Therefore, increases in circulating
VEGF-A and Ang-1 (in the form of Ang-1*) may together
worsen renal inflammation triggered by FA.
Several studies have used ‘vascular growth factors’ to
attempt to treat diverse nephropathies. Most studies have
focused on VEGF, with some reporting beneficial effects, for
example, using subtotal nephrectomy,47 whereas others, for
example, in angiotensin II-induced nephropathy48 showing
modest or no beneficial effects on renal microvessels, tubules,
or interstitial lesions. It appears that in the context of FA
nephropathy, Ang-1* has both vessel stabilizing, profibrotic,
and inflammatory effects; in fact, this accords with
some previous observations such as those of De Palma,33
linking monocytes to angiogenesis and pericyte formation.
Furthermore, other reports in specific murine and
human nephropathies suggest that angiogenesis positively
correlates with the severity of tubulointerstitial lesions and
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inflammation.49,50 Recently, Kim et al.15 investigated the
effects of adenoviral Ang-1 overexpression in a model of
unilateral ureteric obstruction in mice. Similar to our
observations, they demonstrated that Ang-1 maintained the
endothelium, but in addition reported an amelioration of
renal fibrosis. There are several explanations for the
discrepancy between this and the current study. First, in
the ureteric obstruction model, cartilage oligomeric matrix
protein-Ang-1, was used. Cartilage oligomeric matrix pro-
tein-Ang-1 is more potent than native Ang-1 in phosphor-
ylating Tie-25 and can also activate the structurally related
Tie-1 receptor.6 Tie-1 activation can modulate endothelial
cell survival6 but its role in the normal or diseased kidney is
currently unknown. It should also be noted that Ang-1*
incorporates a portion of Ang-2 which could contribute to
the inflammatory responses seen in this study. Second, the
serum levels of cartilage oligomeric matrix protein-Ang1
were over 200 ng/ml 1 month into the protocol,15 whereas the
dose of adenovirus used in the current study led to lower
circulating Ang-1* levels 3 weeks after exposure to FA.
Finally, the levels of endogenous kidney Ang-1 in each model
are different. FA nephropathy leads to upregulation of
Ang-1,18 whereas ureteric obstruction leads to an Ang-1
depletion.15 In future, it would be informative to explore the
effects of the Ad-Ang-1* vector on obstructive nephropathy,
and also to use the Ad-cartilage oligomeric matrix protein-
Ang-1 vector to treat FA nephropathy.
MATERIALS AND METHODS
Experimental strategy
Reagents were obtained from Sigma Chemical Company (Poole,
UK) unless otherwise stated. Eight week-old male C57Bl/6J mice
(Charles River Laboratories, Margate, UK), of average weight 25 g,
were used in protocols approved by the Home Office. The three key
experimental groups are depicted in Figure 1. Group I (n¼ 7), the
‘sham controls’, were administered intravenous (i.v.) PBS (phos-
phate-buffered saline, 0.1 ml, pH 7.4; the vehicle used for adenovirus
administration) at day 0 and then intraperitoneal (i.p.) sodium
bicarbonate (NaHCO3, 0.2 ml, 0.3 M; the vehicle used for FA
administration) at day 5; they were killed at day 26. Groups II
and III were used to induce FA nephropathy. We performed pilot
studies and determined that a 240 mg/g body weight i.p. FA dose
reliably caused ‘acute tubular necrosis’ in all mice, with a low
mortality rate (about 5%) over 21 days observation. Group II
(n¼ 16), the ‘negative control adenovirus group’, were administered
i.v. Ad-GFP (109 PFU (plaque forming unit) in 0.1 ml of PBS) on
day 0 and then i.p. FA at day 5 of the protocol. Group III (n¼ 16),
the ‘active adenovirus group’, were administered i.v. Ad-Ang-1*
(109 PFU in 0.1 ml of PBS) on day 0 and then i.p. FA at day 5 of the
protocol. In Groups II and III, one mouse died spontaneously at day
6 and, of the remainder, eight were killed at day 7 and seven at day
26 of the protocol (that is, respectively, 2 and 21 days after induction
of acute nephrotoxicity). Ang-1* codes for a recombinant form of
human Ang-1 with a modified N-terminal sequence and a Cys245
mutation facilitating synthesis and purification.19 Intravenous
administration of 109 PFU Ad-Ang-1* into adult C57Bl/6J mice
was reported to lead to liver transduction, with circulating Ang-1*
protein detected after 6 hours, and serum levels of 10 mg/ml at
3 days.19 Furthermore, administration of this dose of Ad-Ang-1* to
nude CD1 mice, which probably would not clear the virus as rapidly
as wild types, was reported to have no significant effects on body
weight, systolic blood pressure, or levels of blood urea or creatinine
over a 25-day period when serum levels of Ad-Ang-1* were
100–2000 ng/ml.19
Histology and blood analyses
Body and kidney weights were measured and right-sided kidneys used
for histology and left-sided kidneys for biochemical studies. Blood was
collected by exsanguination and creatinine, and urea measured by an
automated analyzer and serum Ad-Ang-1* levels measured by ELISA,
as described.19 Overnight urine was collected in metabolic cages at
either day 18 or 19 of the protocol. Urine volume was recorded and
albumin concentrations measured by ELISA (Bethyl Laboratories,
Montgomery, TX, USA).51 Kidneys were fixed in 4% paraformalde-
hyde or 10% formalin solution and 5mm sections were dewaxed and
rehydrated. Immunohistochemistry was performed as described18 for
primary antibodies: rat anti-mouse PECAM-1 (Pharmingen, San
Diego, CA, USA), rat anti-mouse macrophage marker (F4/80; Serotec,
Raleigh, NC, USA), rat anti-mouse neutrophil (MCA771G; Serotec),
goat anti-human collagen I (Southern Biotech, Birmingham, AL,
USA), goat anti-human collagen III (Southern Biotech), and mouse
anti-human a-SMA (Dako, High Wycombe, UK). Negative controls
consisted of omission of primary antibodies or substitution with
preimmune serum. Some sections were stained with either PAS
(periodic acid Schiff) reagent and/or hematoxylin. Masson’s trichrome
staining was used to identify fibrotic cortical interstitial areas.52 We
averaged the percentage of squares in 10 10 grids in 15–25 sequential
fields at  200 magnification showing blue-green color. Using this
method, the areas of the kidney cortex containing macrophages or
neutrophils were determined. Peritubular capillary area (assessed by
PECAM-1 immunostaining) and deposition of collagen I and III was
analyzed as a percentage of the whole image using Image J software
(http://rsbweb.nih.gov.ij/).16 Percentages of glomeruli surrounded by
a-SMA-expressing cells were determined by examination of at least 50
glomeruli for each sample. For transmission electron microscopy,51
kidney cortex specimens (1 mm3) were postfixed in osmium tetroxide,
dehydrated in acetone, and embedded in epoxy resin: ultrathin
sections were stained with uranyl-acetate and lead citrate.
Cell culture
Murine macrophage-like cells (RAW 264.7;53 American Type
Culture Collection, Manassas, VA, USA) were maintained in
Dulbecco’s modified Eagle’s medium (Invitrogen, Paisley, UK) with
10% fetal calf serum and 4 mM L-glutamine. Once confluent, RNA
and protein were extracted for further analysis.
Real-time polymerase chain reaction
RNA was extracted using Tri-Reagent from both whole kidneys of
animals in Groups II and III or RAW 264.7 cells and 1 mg used to
prepare cDNA. Quantitative RT-PCR was performed for Ang-1,
Ang-2, Tie-1, Tie-2, a-SMA, collagen I, fibronectin, and TGF-b1
(transforming growth factor-b1) using previously described meth-
ods10 with HPRT (hypoxanthine-guanine phosphoribosyltransfer-
ase) as a housekeeping gene. We used published primers51,54–57
except those for Ang-1, designed using the Primer 3 program
(http://primer3.sourceforge.net): sense 50-GATCTTACACGGTGCC
GATT-30 (corresponding to nucleotides 1588–1607, GenBank
accession number U83509) and antisense 50-TGATTTTGTCC
CGCAGTGTA-30 (corresponding to nucleotides 1718–1737)
Kidney International (2008) 74, 300–309 307
DA Long et al.: Angiopoietin-1 therapy in nephropathy o r i g i n a l a r t i c l e
resulting in a 150-base pair product. cDNA from adult mouse
kidney was used as a positive control. Negative controls lacked
reverse transcriptase or a cDNA template.
Western blotting
Western blotting was performed on 80 mg of protein prepared from
either whole kidneys from Groups II and III or RAW 264.7 cells as
previously described.18 Blots were incubated at 41C overnight with
mouse anti-human a-SMA, rabbit anti-human Tie-1, and Tie-2
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and
bands detected by chemiluminescence. Blots were stripped and then
reprobed for either GAPDH (Abcam, Cambridge, UK) or b-actin as
a housekeeping gene. Band intensity was measured by densitometry.
ELISA
Protein levels of MCP-1 and VEGF were assessed in whole-kidney
tissues or serum by immunoassay (R&D Systems, Minneapolis, MN,
USA).
Statistics
Data were presented as means±standard error of the mean (s.e.m.).
As the scatter of data was consistent with a Gaussian distribution,
differences in the various parameters between groups were
evaluated by a one-tail, unpaired t-test. Po0.05 was considered
significant.
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